Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Baseline levels and median changes in insulin, glucose, IGF1/IGFBP1

From: Safety and feasibility of fasting in combination with platinum-based chemotherapy

Biomarker cohort Baseline Median % change after 1st fast Median % change after 2nd fast P value
Insulin 0.35*, 0.50**
 24 h (n = 4) 6.95 (2.61, 18.55) −56 % (−88 %, 65 %) −48 % (−92 %, 242 %)
 48 h (n = 6) 4.86 (2.08, 11.38) −27 % (−77 %, 131 %) 92 % (−57 %, 747 %)
 72 h (n = 7) 8.30 (4.15, 16.61) −42 % (−73 %, 49 %) −55 % (−85 %, 37 %)
Glucose 0.13*, 0.74**
 24 h (n = 4) 95.9 (83.8, 109.7) 3 % (−12 %, 22 %) 13 % (−4 %, 33 %)
 48 h (n = 6) 92.2 (82.6, 102.9) 14 % (−1 %, 30 %) 13 % (−4 %, 32 %)
 72 h (n = 7) 98.4 (88.9, 109.0) −3 % (−14 %, 9 %) −6 % (−18 %, 9 %)
IGF-1 (ng/mL) 0.32*, 0.28**
 24 h (n = 4) 242 (185, 315) −30 % (−44 %, −12 %) −31 % (−45 %, −13 %)
 48 h (n = 5) 177 (139, 225) −33 % (−45 %, −18 %) −20 % (−37 %, 1 %)
 72 h (n = 5) 163 (128, 207) −8 % (−24 %, 13 %) 16 % (−5 %, −42 %)
IGFBP1 (ng/mL) 0.09*, 0.61v
 24 h (n = 4) 8.9 (5.7, 14) 23 % (−19 %, 87 %) 63 % (7 %, 147 %)
 48 h (n = 5) 8.8 (5.9, 13) 10 % (−24 %, 60 %) 5 % (−32 %, 63 %)
 72 h (n = 5) 3.8 (2.6, 5.7) 117 % (49 %, 215 %) 74 % (20 %, 153 %)
B-hydroxybutyrate 0.12*, 0.037**
 24 h (n = 4) 0.21 (0.13, 0.36) −16 % (−48 %, 37 %) −13 % (−47 %, 49 %)
 48 h (n = 5) 0.14 (0.09, 0.23) 272 % (140 %, 470 %) 82 % (9 %, 204 %)
 72 h (n = 5) 0.12 (0.08, 0.19) 181 % (81 %, 334 %) 24 % (−20 %, 92 %)
  1. These are presented only for self-reported compliant patients, and only for those with pre- and post-fasting samples available, separated by fasting duration cohort. The post-fasting blood draws were taken after 24 h of fasting in the 24 h cohort, and after 48 h of fasting in both the 48 and 72 h cohorts, and were done prior to any premedications or chemotherapy
  2. *p-value comparing changes in levels from baseline, between the 3 fasting cohorts
  3. **p-value comparing changes from baseline between the 24 h cohort compared to the 48 + 72 h cohorts combined